ECLIPSE OPERATIONS, LLC

Q2 2022 13F Holdings Report, Stock Holdings

Signature - Title
Greg Lyon - Chief Financial Officer
Location
Palo Alto, CA
Holdings as of
30 Jun 2022
Value $
$216,680,000
Num holdings
3
Filing time
11 Aug 2022, 13:02:04 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included ENVX, OWLT, and LHDXQ.
Previous filing
Q1 2022 - 27 Apr 2022
Next filing
Q3 2022 - 14 Nov 2022

Quoteable Key Fact

"ECLIPSE OPERATIONS, LLC reported $216,680,000 across 3 holdings in Q2 2022."

Quick Takeaways

  • ECLIPSE OPERATIONS, LLC reported 13f holdings report, stock holdings for Q2 2022.
  • Reported holdings value: $216,680,000.
  • 3 holdings are listed in this filing snapshot.

What Changed

  • Previous comparable filing: Q1 2022.
  • Value moved from $399,922,917 to $216,680,000.

Why This Matters

  • This filing-level page explains what the portfolio report tells you before the holdings table.
  • You can cite quarter, value, and filing timestamp directly from SEC-linked data.

Source Evidence

Backed by Form 13F

Portfolio-level numbers on this page come from the original SEC Form 13F filing.

See Original Filing
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2022 Q2 compared to 2022 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Greg Lyon Chief Financial Officer Palo Alto, California 09 Aug 2022
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .